91 91 correctly predicted forecasts
Send me real-time posts from this site at my email

​Tonight’s Action List for Tomorrow, Tuesday, March 21 2017

  • 1.Clear skies are ahead for shares of Alibaba (BABA). At ~ $107, the stock faces no real resistance until the $120 share price range.
  • 2.Snap Inc. (SNAP) won the cliché headline of “snapping back” after the stock received its first ‘buy’ rating. The stock is for traders. It is no Amazon.com or Netflix. Buy the user activity growth numbers but sell the stock when markets worry over years of losses ahead for SNAP.
  • 3.Advanced Micro Devices (AMD) surged higher after Jefferies gave a PT $17 (price target = PT). This group has a $15 PT for now and a higher target, pending Ryzen sales figures.
  • 4.Aurinia Pharmaceuticals (AUPH) is rebounding after the markets decided the stock offering, at a big discount, is not a bad thing. AUPH is diluting stock holders. This is a bad thing. The ~23M share offer will give the company plenty of cash. Now it must spend it wisely on lupus nephritis development. After approval (if…), AUPH must bring the drug to market.
  • 5.FireEye (FEYE) rose 9% after an analyst upgrade. Fundamentals are poor and valuations are unfavorable for FEYE.
  • 6.Another day, another new high for Apple, Inc. PT: $1 trillion market cap.

iPhone 8, 9, 10: Magical

  • 7.Micron Technology (MU) is reporting results on March 23. Expect a good report, though any weak outlook may send the stock lower.
  • 8.First Solar (FSLR) failed to hold the $30 level. The problem is clear: the market expects a trade war with China, excess output, and weak pricing for solar panels. FSLR, unfortunately, will trade lower on the markets. A buying, entry point will arrive soon.\
  • 9.DRYS fell nearly 20%. As I post nearly daily, DRYS is a stock you should sell. Get anything you can for it and move on.
  • 10.“Like” this post to “ping” members on the Value Stocks group. Login via StockTwits to post your move in the comments, below. This group is just 10 users short of 600 members.
  • 91 91 correctly predicted forecasts
    Chris Lau
    DUH. $MVIS +25% should be on this list. For investors, $MU ER on March 23 will be watched by many value investors in this group.
    Reply
    1
  • 117 117 correctly predicted forecasts
    Max Grigoryev
    AMD is on top of watch list as usual
    FEYE got upgraded, so might bounce back a bit tomorrow
    Totally agree on SNAP, just the catchy headlines helped the stock to slightly recover
    Reply
    1
  • 91 91 correctly predicted forecasts
    Chris Lau
    Max, $SNAP back to $25, even. but why take on that risk of holding it down to $14-$16? Better gambles elsewhere, like $MVIS $HIMX $BABA $TWTR. $FB's a "sure thing" it seems.
    Reply
    0
  • 117 117 correctly predicted forecasts
    Max Grigoryev
    Chris, yeah, $FB keeps going up
    Reply
    1
  • 74 74 correctly predicted forecasts
    Long/Short Investments
    Max, Ugh, I missed out badly on $FB. Probably best business model in the world outside of $GOOG.
    Reply
    1
  • 91 91 correctly predicted forecasts
    Chris Lau
    Long/Short, I missed it so badly too. The bottom was staring me in the face but I did not buy. Well done, FB for having ~ 1B daily active users.
    Reply
    1
  • 74 74 correctly predicted forecasts
    Long/Short Investments
    Chris, Selling $AAPL at $97-$107 last year was another stupid move of mine in retrospect. Still think they have issues in the saturated smartphone market moving forward, but they've done a good job building out their network and their marketing is first-class.
    Reply
    0
  • Chris
    Max, It is really nice. I bought FB in past week!
    Reply
    2
  • 91 91 correctly predicted forecasts
    Chris Lau
    Valeant update - from Barron's:
    For the week ending March 10th, new derm scripts (NRx) were up 4.5% vs. down 4.7% the prior week. Derm NRx are down 49.8% YoY on a 4-week rolling basis vs. 49.8% the prior week. We view this continued downward trend negatively but note that we cannot track net pricing levels…

    Xifaxan 550mg TRx was down 1.9% YoY (vs. down 2.5% YoY last week), with TRx up 0.1% WoW vs. up 3.4% last week. We continue to note that Xifaxan is now trending down YoY…but view the WoW TRx improvement (two-consecutive weeks) positively and will closely monitor next week’s scripts.
    Reply
    0
Cancel